Tau

News

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Roche has won US FDA clearance for a blood test that could move Alzheimer’s biomarker testing further into primary care.

News

Tauklarify PET approval for Lantheus in AD NFT pathology

The FDA approves Lantheus' Tauklarify radiodiagnostic PET to evaluate NFT pathology in Alzheimer's disease.

News

Biogen, Ionis trumpet Alzheimer's data, but shares dip

Biogen and Ionis have revealed the first clinical results with tau-targeting Alzheimer's drug candidate diranersen, to a mixed response.

News

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

Biogen will advance its tau-targeting Alzheimer's disease drug diranersen into phase 3, even though it missed the main endpoint in a midstage trial.

News

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.

R&D

Advancements in early detection and innovative therapies tar...

Alzheimer’s disease (AD) robs millions of individuals of their memories, cognitive function, and independence, placing an immense emotional and financial burden on families and healthcare s

FDA greenlights Roche’s biomarker blood test for Alzheimer's

Tauklarify PET approval for Lantheus in AD NFT pathology

Biogen, Ionis trumpet Alzheimer's data, but shares dip

Trial miss doesn't dent Biogen's faith in Alzheimer's drug

J&J abandons Alzheimer's antibody in setback for tau

Advancements in early detection and innovative therapies tar...

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Tau

Editor's Picks